A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis

Study map

Overview / Summary

Study details

Participating countries are:

Germany (1 site)

Italy (1 site)

Greece (1 site)

France (1 site)

Netherland (1 site)

UK (1 site)

Patient eligibility criteria

Patients with relapsed or refractory AL amyloidosis, with adequate organ reserve and measurable hematologic disease


No publications connected to this trial at the moment